The last few years have been dominated by the global fight against COVID-19 and research efforts continue in search of new treatments and vaccines to save lives.
Melbourne-based Dimerix Bioscience is a clinical-stage biopharmaceutical company investigating a new treatment for respiratory complications as a result of COVID 19 – which was selected for inclusion in the global WHO-endorsed clinical study REMAP-CAP investigating community-acquired pneumonia.
Through MTPConnect’s Biomedical Translation Bridge (BTB) Program, Dimerix was awarded $1 million in MRFF-funding for this COVID-19 related project.
MTPConnect host Caroline Duell catches up with Dr Robert Shepherd, Research & Development Director at Dimerix Bioscience to find out more about this potential new treatment, the benefits and challenges of being part of a unique adaptive clinical trial program and how they managed to manufacture doses for the trial during the pandemic. https://dimerix.com/
Uniquest is a Venture Partner in the BTB Program, and Cecile Francis, Uniquest’s BTB Program Project Manager joins the discussion. https://uniquest.com.au/
